EX9.F Exelixis Inc

Healthcare Biotechnology Frankfurt Exchange
62.93 EUR
Close of Nov 12, 2026
34.18 66.62
Market cap
EUR 15.4B
P/E
21.8x
P/B
9.45x
ROE
46.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EX9.F undervalued?

Graham number

The Graham number of Exelixis Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Exelixis Inc fundamental analysis

No fundamental analysis for Exelixis Inc yet.

Exelixis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibito…

Full company profile